Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Severe radiodermatitis and implant loss associated with pembrolizumab and olaparib following pre-pectoral breast reconstruction in a 31-year-old female: a case report.AME case reports · 2026
   Article
2. AI-enabled precision prediction and proactive management of cutaneous toxicities in cancer immunoradiotherapy (ICI+RT).Frontiers in oncology · 2026
   Review
3. Radiation recall dermatitis in cancer patients previously undergoing radiotherapy: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
   Article
4. Pembrolizumab-Associated Severe Radiation Recall Dermatitis in a Patient with Metastatic Head and Neck Carcinoma: A Case Report.Case reports in oncology
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as